Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

A Study of RO4917523 in Patients With Treatment Resistant Depression

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00809562
Recruitment Status : Completed
First Posted : December 17, 2008
Last Update Posted : November 2, 2016
Information provided by (Responsible Party):
Hoffmann-La Roche

Brief Summary:
This study will evaluate the safety, tolerability and efficacy of RO4917523, in comparison to placebo, in patients with treatment-resistant depression. Following a washout period from existing anti-depressant medication, cohorts of patients will be randomized to receive daily oral RO4917523 at up to five different doses (according to the safety and tolerability observed at the lower doses during the study), or placebo. The anticipated time on study treatment is 10 days (in an inpatient unit), and the target sample size is <100 individuals.

Condition or disease Intervention/treatment Phase
Depression Drug: Placebo Drug: RO4917523 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 46 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: An Exploratory Fixed Dose Randomized Double Blind Parallel-group Placebo-controlled Study of the Safety and of the Therapeutic Effects of Ro 4917523 in Patients With Treatment- Resistant Depression
Study Start Date : March 2009
Actual Primary Completion Date : February 2011
Actual Study Completion Date : February 2011

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: 1 Drug: RO4917523
orally daily for 10 days, cohorts receiving up to 5 different doses (according to safety and tolerability)

Placebo Comparator: 2 Drug: Placebo
po daily for 10 days

Primary Outcome Measures :
  1. Safety and tolerability: Adverse events, ECGs, laboratory parameters,vital signs [ Time Frame: Throughout study ]

Secondary Outcome Measures :
  1. Efficacy: MADRS score [ Time Frame: From baseline to day 10 ]
  2. Symptoms of treatment-resistant depression [ Time Frame: Throughout study ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • adult patients, 18-65 years of age;
  • recurrent major depressive disorder, without psychotic features;
  • at least 3 lifetime treatment failures, at least 2 of which must have occurred within the current depressive episode;
  • baseline minimal severity defined by a HAM-D score of 18 or above;
  • willing to be hospitalized for at least 16 consecutive days.

Exclusion Criteria:

  • history of bipolar disorder, schizoaffective disorder or schizophrenia;
  • history of psychosis, including psychotic depression;
  • significant past or present neurological disorder, including seizures, stroke and/or head trauma.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00809562

Layout table for location information
United States, California
Oceanside, California, United States, 92056
San Diego, California, United States, 92103
United States, Connecticut
New Haven, Connecticut, United States, 06511
United States, Louisiana
Shreveport, Louisiana, United States, 71115
United States, Mississippi
Flowood, Mississippi, United States, 39232
United States, New York
New York, New York, United States, 10029
New York, New York, United States, 10032
New York, New York, United States, 10065-4870
United States, Pennsylvania
Pittsburgh, Pennsylvania, United States, 15213
Sponsors and Collaborators
Hoffmann-La Roche
Layout table for investigator information
Study Director: Clinical Trials Hoffmann-La Roche
Layout table for additonal information
Responsible Party: Hoffmann-La Roche Identifier: NCT00809562    
Other Study ID Numbers: NP22022
First Posted: December 17, 2008    Key Record Dates
Last Update Posted: November 2, 2016
Last Verified: November 2016
Additional relevant MeSH terms:
Layout table for MeSH terms
Depressive Disorder
Depressive Disorder, Treatment-Resistant
Behavioral Symptoms
Mood Disorders
Mental Disorders